---
import BaseLayout from '../../layouts/BaseLayout.astro';
import MedicalDisclaimer from '../../components/MedicalDisclaimer.astro';

const affiliateLinks = { medvi: 'https://medvi.org/?page=multi&uid=5&oid=2&affid=2&pol=5&sub1=1350&sub1=1350&oid2=4412&affid2=1350' };
---

<BaseLayout 
  title="Best Weight Loss Peptides in 2026: Complete Ranking & Comparison"
  description="Ranking the best peptides for weight loss: Retatrutide (24-28.7%), Tirzepatide (15-22.5%), Semaglutide (10-15%). Compare effectiveness, cost, availability."
>
  <style>
    .hero { background: linear-gradient(135deg, #6366f1 0%, #4f46e5 100%); color: white; padding: 80px 24px 60px; text-align: center; }
    .hero h1 { font-size: clamp(2rem, 5vw, 2.8rem); font-weight: 700; margin-bottom: 16px; line-height: 1.2; }
    .content { max-width: 900px; margin: 0 auto; padding: 60px 24px 120px; }
    .content h2 { font-size: 2rem; font-weight: 700; margin: 48px 0 16px; }
    .content p { font-size: 1.05rem; line-height: 1.7; color: #4b5563; margin-bottom: 20px; }
    .content ol { margin: 20px 0; padding-left: 24px; }
    .content li { font-size: 1.05rem; line-height: 1.7; color: #4b5563; margin-bottom: 24px; }
  </style>

  <div class="hero">
    <h1>Best Weight Loss Peptides in 2026: Complete Ranking</h1>
    <p>Comparing retatrutide, tirzepatide, semaglutide, CagriSema, and more. Which peptide is right for you?</p>
  </div>

  <div class="content">
    <h2>Ranking: Best to Worst by Weight Loss Effectiveness</h2>

    <ol>
      <li>
        <strong>Retatrutide (24-28.7% weight loss)</strong><br/>
        Triple agonist (GLP-1/GIP/Glucagon). Best results but not available until 2027-2028. Clinical trials only.<br/>
        <em>Status: Phase 3 trials</em>
      </li>

      <li>
        <strong>Tirzepatide (15-22.5% weight loss)</strong><br/>
        Dual agonist (GLP-1/GIP). Best CURRENTLY available option. $179-499/month compounded.<br/>
        <em>Status: FDA approved, available now</em>
      </li>

      <li>
        <strong>CagriSema (15-20% weight loss estimated)</strong><br/>
        Dual agonist (Amylin + GLP-1). Novo Nordisk's answer to tirzepatide. Not available yet.<br/>
        <em>Status: Phase 3 trials, expected 2027</em>
      </li>

      <li>
        <strong>Survodutide (15-19% weight loss)</strong><br/>
        Dual agonist (GLP-1/Glucagon). Boehringer Ingelheim. Similar to tirzepatide but years away.<br/>
        <em>Status: Phase 3 trials, expected 2028+</em>
      </li>

      <li>
        <strong>Semaglutide (10-15% weight loss)</strong><br/>
        Single agonist (GLP-1). Proven, safe, 5+ years real-world use. $179-349/month compounded.<br/>
        <em>Status: FDA approved, available now</em>
      </li>

      <li>
        <strong>Orforglipron (8-15% weight loss)</strong><br/>
        Oral GLP-1 pill. Convenient (no injections) but less effective than injectable peptides.<br/>
        <em>Status: Phase 3 trials, expected 2028</em>
      </li>
    </ol>

    <h2>Best Overall: Tirzepatide (Available Now)</h2>
    <p><strong>Why tirzepatide wins:</strong></p>
    <ul style="list-style: none; padding: 0;">
      <li>✅ Excellent results (15-22.5% weight loss)</li>
      <li>✅ Available TODAY through telemedicine</li>
      <li>✅ Affordable at $179-499/month compounded</li>
      <li>✅ 2+ years real-world safety data</li>
      <li>✅ No waiting until 2027-2028</li>
    </ul>

    <h2>Best Future Option: Retatrutide (2027-2028)</h2>
    <p>If you can wait 1-2 years, retatrutide will likely be the most effective option. But most people should start tirzepatide NOW and switch later if needed.</p>

    <div style="background: linear-gradient(135deg, #10b981 0%, #059669 100%); color: white; border-radius: 12px; padding: 40px 32px; text-align: center; margin: 48px 0;">
      <h3 style="font-size: 1.8rem; font-weight: 700; margin-bottom: 12px;">Start the Best Available Peptide Today</h3>
      <p style="font-size: 1.05rem; opacity: 0.95; margin-bottom: 24px;">Tirzepatide: 15-22.5% weight loss, available now, $179/month</p>
      <a href={affiliateLinks.medvi} target="_blank" rel="noopener sponsored" style="background: white; color: #059669; padding: 14px 28px; border-radius: 8px; font-weight: 700; text-decoration: none; display: inline-block;">Start with MEDVi →</a>
    </div>

    <MedicalDisclaimer />
  </div>
</BaseLayout>
